270
Haslett, C.; Douglas, J.G.; Chalmers, S.; Weighhill, V.E.; Munro, J.F. A placebo-controlled trial of Efamol (evening primrose oil) in the treatment of human obesity
In: Horrobin D.F. (Ed.) Clinical Uses of Essential Fatty Acids. Eden Press, Montreal. 1982: 63-71.
271
Horrobin, D.F. A possible biochemical basis for alcoholism and schizoid reactions during alcohol withdrawal
In: Hemmings, G. (Ed.) Biological Aspects of Schizophrenia and Addiction. Wiley. 1982: 163-171. (Abstract)
272
Horrobin, D.F. Prostaglandins, essential fatty acids and psychiatric disorders: a background review
In: Horrobin D.F. (Ed.) Clinical Uses of Essential Fatty Acids. Eden Press, Montreal. 1982: 167-174.
273
Horrobin, D.F. Essential fatty acids: a review
In: Horrobin D.F. (Ed.) Clinical Uses of Essential Fatty Acids. Eden Press, Montreal. 1982: 3-36.
274
Horrobin, D.F. The lowering of plasma cholesterol levels by essential fatty acids
In: Horrobin D.F. (Ed.) Clinical Uses of Essential Fatty Acids. Eden Press, Montreal. 1982: 89-96.
275
Horrobin, D.F. Possible roles of prostaglandins in mediating opioid actions
In: Shah, N.S.; Donald, A.G. (Eds.) Endorphins and Opiate Antagonists in Psychiatric Research. Plenum, New York. 1982: 75-87.
276
Horrobin, D.F. Diazepam and cancer
Lancet 1982; 2(8291): 223.
277
Horrobin, D.F. In praise of non-experts
New Scientist 1982; 94(1311): 842-844.
278
Horrobin, D.F. Clinical forum. 5 - schizophrenia: the body in question
Nurs Mirror 1982; 154(20): vi-viii.
279
Horrobin, D.F. Prostaglandin E1 and the nutritional regulation of its formation: roles in the skin, the female reproductive system, the immune system and in the brain
Swed J Biol Med 1982; 1: 13-17.
280
Horrobin, D.F. Peer review: A philosophically faulty concept which is proving disastrous for science
The Behavioral and Brain Sciences 1982; 5(2): 217-218.
281
Horrobin, D.F. (ed.) Clinical uses of essential fatty Acids
Eden Press, Montreal. 214pp 1982.
282
Huang, Y.S.; Cunnane, S.C.; Horrobin, D.F.; Davignon, J. Most biological effects of zinc deficiency corrected by gamma-linolenic acid (18:3 omega-6) but not by linoleic acid (18:2 omega- 6)
Atherosclerosis 1982; 41(2-3): 193-207.
283
Linder, P.G.; Bristrian, B.R.; Bray, G.A.; Collipp, P.J.; Hirsch, J.; Horrobin, D.F. The future of obesity treatment (part I)
Obesity/Bariatric Med 1982; 11(3): 83-88.
284
Lindner, P.G.; Bristrian, B.R.; Bray, G.A.; Collipp, P.J.; Hirsch, J.; Horrobin, D.F. The future of obesity treatment (part II)
Obesity/Bariatric Med 1982; 11(4): 110-114.
285
Lowndes, R.H. and Mansel, R.E. The effects of evening primrose oil administration on the serum lipids of normal and obese human subjects
In: Horrobin D.F. (Ed.) Clinical Uses of Essential Fatty Acids. Eden Press, Montreal. 1982: 37-52.
286
Manku, M.S. and Horrobin, D.F. Essential fatty acid levels in the plasma of patients with atopic eczema
In: Horrobin D.F. (Ed.) Clinical Uses of Essential Fatty Acids. Eden Press, Montreal. 1982: 81-88.
287
Manku, M.S.; Horrobin, D.F.; Morse, N.; Kyte, V.; Jenkins, K.; Wright, S.; Burton, J.L. Reduced levels of prostaglandin precursors in the blood of atopic patients: defective delta-6-desaturase function as a biochemical basis for atopy
Prostaglandins Leukot Med 1982; 9(6): 615-28. (Abstract)
288
Smith, D.F. and Horrobin, D.F. Lithium and animal behaviour
Kluwer Academic Publishers, 134pp 1982.